Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 16 to 30 of 62 results for ibd

  1. Immunoscore for predicting risk of colon cancer relapse (MIB269)

    NICE has developed a medtech innovation briefing on Immunoscore for predicting risk of colon cancer relapse .

  2. Clostridioides difficile infection: antimicrobial prescribing (NG199)

    This guideline sets out an antimicrobial prescribing strategy for managing Clostridioides difficile infection in adults, young people and children aged 72 hours and over in community and hospital settings. It aims to optimise antibiotic use and reduce antibiotic resistance. The recommendations do not cover diagnosis.

  3. Manchester Royal Infirmary Virtual Biologics Clinic

    gastroenterology and dermatology, including at an event for the National IBD audit. Implementing up-to-date high-quality research...

  4. Colonoscopic surveillance in adults with Ulcerative colitis, Crohn's disease or adenomas - Is this happening?

    and over with ulcerative colitis or Crohn's disease (types of inflammatory bowel disease) or adenomas (also known as polyps). It aims to...

  5. eXroid for internal haemorrhoids (MIB201)

    NICE has developed a medtech innovation briefing (MIB) on eXroid for internal haemorrhoids .

  6. Bioprosthetic plug insertion for anal fistula (IPG662)

    Evidence-based recommendations on bioprosthetic plug insertion for anal fistula in adults. This involves putting a plug into the fistula and stitching it in place.

  7. Multiple long-term conditions: medication review (IND207)

    This indicator covers the percentage of patients with moderate or severe frailty and/or multimorbidity who have received a medication review in the last 12 months which is structured, has considered the use of a recognised tool and taken place as a shared discussion. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM186

  8. Multiple long-term conditions: multimorbidity register (IND205)

    This indicator covers the practice can produce a register of people with multimorbidity who would benefit from a tailored approach to care. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM184

  9. Reinforcement of a permanent stoma with a synthetic or biological mesh to prevent a parastomal hernia (IPG654)

    Evidence-based recommendations on reinforcement of a permanent stoma with a synthetic or biological mesh to prevent a parastomal hernia. This involves inserting a piece of mesh to strengthen the abdominal wall.

  10. Collagen paste for closing an anal fistula (IPG648)

    Evidence-based recommendations on collagen paste for closing an anal fistula in adults. This involves using the paste to fill the fistula to seal it. The aim is to encourage healing.

  11. Ulcerative colitis: management (NG130)

    This guideline covers managing ulcerative colitis in children, young people and adults. It aims to help professionals to provide consistent high-quality care and it highlights the importance of advice and support for people with ulcerative colitis.

  12. Endoscopic ablation for an anal fistula (IPG645)

    Evidence-based recommendations on endoscopic ablation for an anal fistula in adults. This involves applying heat to the fistula.

  13. PredictSure-IBD for inflammatory bowel disease prognosis (MIB178)

    This medtech innovation briefing has been updated and replaced by NICE medtech innovation briefing 313.

  14. Radially emitting laser fibre treatment of an anal fistula (IPG644)

    Evidence-based recommendations on radially emitting laser fibre treatment of an anal fistula in adults. This involves applying laser energy to the fistula.

  15. Tofacitinib for moderately to severely active ulcerative colitis (TA547)

    Evidence-based recommendations on tofacitinib (Xeljanz) for previously treated moderately to severely active ulcerative colitis in adults.